Clinical Trial: A Phase 3 Trial of MM120 for Generalized Anxiety Disorder

U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06809595) titled 'A Phase 3 Trial of MM120 for Generalized Anxiety Disorder' on Jan. 30.

Brief Summary: A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama

Study Start Date: Jan. 29

Study Type: INTERVENTIONAL

Condition: Generalized Anxiety Disorder

Intervention: OTHER: Placebo

A substance that is designed to have no therapeutic value

DRUG: MM120 (LSD D-Tartrate)

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

Recruitment Status: RECRUITING

Sponsor...